EZH2 and prostate carcinoma: An outlier case was P001, a patient with an MMR-defective prostate cancer who had the highest mutation burden, including several shared mutations between primary and mCRPC (APC, CDK12, MSH6, ERBB4, PTEN, and TP53), several private mutations only detected in mCRPC (including missense, nontruncating mutations in APC, ATM, EZH2, JAK1), and several private mutations of the primary tumor not detected in the later mCRPC biopsy (CTNNB1, PRKDC, ERCC3, and ERRC6), suggesting the presence of different clones coming from a shared origin.